Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort
Use of BBs and ACEi/ARBs has increased over time, particularly in advanced-stage ATTR-CA patients, and although these therapies appear to be reasonably tolerated, survival was not significantly altered.
Authors
- Philippe Debonnaire (ORCID: https://orcid.org/0000-0003-1196-3016)
- Dorien Laenens (ORCID: https://orcid.org/0000-0001-8906-2395)
- Steven Droogmans (ORCID: https://orcid.org/0000-0003-3985-3249)
- Erwan Donal (ORCID: https://orcid.org/0000-0003-2677-3389)
- Dulce Brito (ORCID: https://orcid.org/0000-0003-1278-1847)
- Mathias Claeys (ORCID: https://orcid.org/0000-0002-3998-5340)
- Philippe B. Bertrand (ORCID: https://orcid.org/0000-0001-6324-6874)
- Nina Ajmone Marsan (ORCID: https://orcid.org/0000-0001-7208-5769)
- Madelien V. Regeer (ORCID: https://orcid.org/0000-0002-1562-8365)
- T Nabeta
- Nico Van de Veire (ORCID: https://orcid.org/0000-0002-5154-1101)
- Fauto Pinto
- Eva H. van der Geest
Institutions
- Leiden University Medical Center (NL)
- AZ Groeninge (BE)
- Agostino Gemelli University Polyclinic (IT)
- Centro Hospitalar Lisboa Norte (PT)
- AZ Sint-Jan (BE)
- Universitair Ziekenhuis Brussel (BE)
- AZ Maria Middelares (BE)
- Ziekenhuis Oost-Limburg (BE)
- Centre Hospitalier Universitaire de Rennes (FR)
- Université de Rennes (FR)
- Kitasato University (JP)
Publication Details
- Journal
- Journal of Cardiovascular Development and Disease
- Published
- 2025-10-11
- DOI
- https://doi.org/10.3390/jcdd12100403
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00